Vectura Group (VEC) Receives Buy Rating from Citigroup
A number of other analysts have also issued reports on the company. Peel Hunt reissued a hold rating on shares of Vectura Group in a research note on Tuesday, September 4th. Numis Securities reissued a buy rating on shares of Vectura Group in a research note on Thursday, August 23rd. JPMorgan Chase & Co. reissued an overweight rating and issued a GBX 140 ($1.82) price target on shares of Vectura Group in a research note on Tuesday, August 21st. Finally, Shore Capital decreased their price target on Vectura Group from GBX 105 ($1.37) to GBX 78 ($1.02) and set a hold rating on the stock in a research note on Monday, July 16th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Vectura Group has a consensus rating of Buy and an average target price of GBX 128.11 ($1.67).
Shares of LON:VEC opened at GBX 74 ($0.96) on Monday. Vectura Group has a 12-month low of GBX 70 ($0.91) and a 12-month high of GBX 166.97 ($2.17).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Read More: Diversification in Investing
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.